A light and hypoxia-activated nanodrug for cascade photodynamic-chemo cancer therapy

2021 ◽  
Author(s):  
Yin Zhong ◽  
Chujie Zheng ◽  
Si Huang ◽  
Jinsheng Huang ◽  
Bo Li ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Combination Therapy ◽  
Drug Treatment ◽  
Drug Bioavailability ◽  
Efficient Strategy ◽  
Single Drug

Combination therapy provides significantly better outcomes than a single drug treatment and becomes an efficient strategy for cancer therapy at present. Owing to the advantages of improved drug bioavailability, decreased...

Hyaluronan based Multifunctional Nano-carriers for Combination Cancer Therapy

2020 ◽  
Vol 20 ◽  
Author(s):  
Menghan Gao ◽  
Hong Deng ◽  
Weiqi Zhang
Keyword(s):  
Cancer Therapy ◽  
Combination Therapy ◽  
Cancer Cells ◽  
Drug Loading ◽  
Tumor Therapy ◽  
Drug Carriers ◽  
Functional Sites ◽  
Therapeutic Modalities ◽  
Combination Cancer Therapy ◽  
Targeting Strategy

: Hyaluronan (HA) is a natural linear polysaccharide that has excellent hydrophilicity, biocompatibility, biodegradability, and low immunogenicity, making it one of the most attractive biopolymers used for biomedical researches and applications. Due to the multiple functional sites on HA and its intrinsic affinity for CD44, a receptor highly expressed on various cancer cells, HA has been widely engineered to construct different drug-loading nanoparticles (NPs) for CD44- targeted anti-tumor therapy. When a cocktail of drugs is co-loaded in HA NP, a multifunctional nano-carriers could be obtained, which features as a highly effective and self-targeting strategy to combat the cancers with CD44 overexpression. The HA-based multidrug nano-carriers can be a combination of different drugs, various therapeutic modalities, or the integration of therapy and diagnostics (theranostics). Up to now, there are many types of HA-based multidrug nano-carriers constructed by different formulation strategies including drug co-conjugates, micelles, nano-gels and hybrid NP of HA and so on. This multidrug nano-carrier takes the full advantages of HA as NP matrix, drug carriers and targeting ligand, representing a simplified and biocompatible platform to realize the targeted and synergistic combination therapy against the cancers. In this review, recent progresses about HA-based multidrug nano-carriers for combination cancer therapy are summarized and its potential challenges for translational applications have been discussed.

Efficacy of Naproxen Plus Gabapentin Vs Naproxen Alone in Relieving Post-Extraction Pain of Impacted Mandibular 3rd Molar

2021 ◽  
Vol 15 (12) ◽  
pp. 3264-3267
Author(s):  
Safia Khatoon ◽  
Muhammad Ilyas Shaikh ◽  
Arslan Mahmood ◽  
Priya Rani Harjani ◽  
Sarang Suresh ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Drug Treatment ◽  
Rating Scale ◽  
Third Molar ◽  
Pain Scale ◽  
Combination Drug ◽  
Impacted Mandibular Third Molar ◽  
Pain Status ◽  
Mandibular Third Molar ◽  
Combination Drug Treatment

Background: Evaluate the efficacy of using combination drug treatment to relieve post extraction pain of impacted mandibular third molar by using Naproxen plus Gabapentin versus Naproxen alone. Aim: To evaluate the efficacy of using combination drug treatment to relieve post extraction pain of impacted mandibular third molar by using Naproxen plus Gabapentin versus Naproxen alone. Methods: Randomized control study, outcome was evaluated by measuring Pre – Operative and 24-Hour Post – Operative Pain status on Visual Analogue Scale and Wong Baker’s Face Pain Rating Scale. Results: Combination therapy (Naproxen and Gabapentin) was effective in significant pain reduction at 12 Hour and 24-Hour Post Extraction period. With 26 patients out 31 presented with Pain Scale of 0 on combination therapy while only 3 out of 31 for naproxen alone after 24 hours. Conclusion: Enhanced effect of combination therapy of naproxen with gabapentin in reducing post extraction pain of impacted mandibular third molar with respect to naproxen alone. Keywords: Naproxen, Gabapentin, Combination Therapy, Post Extraction Pain, Post Extraction Analgesia, Efficacy.

scholarly journals Starting Antihypertensive Drug Treatment With Combination Therapy

Hypertension ◽  
2021 ◽  
Vol 77 (3) ◽  
pp. 788-798
Author(s):  
Zhen-Yu Zhang ◽  
Yu-Ling Yu ◽  
Kei Asayama ◽  
Tine W. Hansen ◽  
Gladys E. Maestre ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Drug Treatment ◽  
Antihypertensive Drug ◽  
Antihypertensive Drug Treatment

Room G, 10/17/2000 9: 00 AM - 11: 00 AM (PS) Predictive Factors for Recurrent PONV Following Single Drug Treatment 

2000 ◽  
Vol 93 (3A) ◽  
pp. A-1146
Author(s):  
Pierre A. Diemunsch ◽  
Christian Conseiller ◽  
Nathalie Clyti ◽  
Jean P. Mamet
Keyword(s):  
Drug Treatment ◽  
Predictive Factors ◽  
Single Drug

Comparison of Sodium Valproate and Phenytoin as Single Drug Treatment in Epilepsy

Epilepsia ◽  
1981 ◽  
Vol 22 (1) ◽  
pp. 27-33 ◽  
Author(s):  
Raad A. Shakir ◽  
Ralph H. Johnson ◽  
David G. Lambie ◽  
lan D. Melville ◽  
Rabindra N. Nanda
Keyword(s):  
Drug Treatment ◽  
Sodium Valproate ◽  
Single Drug

scholarly journals Pharmacophore hybridisation and nanoscale assembly to discover self-delivering lysosomotropic new-chemical entities for cancer therapy

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Zhao Ma ◽  
Jin Li ◽  
Kai Lin ◽  
Mythili Ramachandran ◽  
Dalin Zhang ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cancer Therapy ◽  
Self Assembly ◽  
The Self ◽  
Single Drug ◽  
Drug Nanoparticles ◽  
Lysosomal Dysfunction ◽  
New Chemical Entities ◽  
Autophagy Inhibition

Abstract Integration of the unique advantages of the fields of drug discovery and drug delivery is invaluable for the advancement of drug development. Here we propose a self-delivering one-component new-chemical-entity nanomedicine (ONN) strategy to improve cancer therapy through incorporation of the self-assembly principle into drug design. A lysosomotropic detergent (MSDH) and an autophagy inhibitor (Lys05) are hybridised to develop bisaminoquinoline derivatives that can intrinsically form nanoassemblies. The selected BAQ12 and BAQ13 ONNs are highly effective in inducing lysosomal disruption, lysosomal dysfunction and autophagy blockade and exhibit 30-fold higher antiproliferative activity than hydroxychloroquine used in clinical trials. These single-drug nanoparticles demonstrate excellent pharmacokinetic and toxicological profiles and dramatic antitumour efficacy in vivo. In addition, they are able to encapsulate and deliver additional drugs to tumour sites and are thus promising agents for autophagy inhibition-based combination therapy. Given their transdisciplinary advantages, these BAQ ONNs have enormous potential to improve cancer therapy.

Sign in / Sign up

Export Citation Format

Share Document